Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijo Bilusic

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|January 12, 2021
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?Marijo Bilusic, James L Gulley
Urologic Oncology|February 12, 2015
Targeted radionuclides for prostate cancer bone metastasesTimothy Ito, Marijo Bilusic, David Chen
BMC Nephrology|November 24, 2016
Nivolumab-associated acute glomerulonephritis: a case report and literature reviewKyungsuk Jung, Xu Zeng, Marijo Bilusic
Vaccine|July 12, 2011
Immunotherapy in prostate cancer: emerging strategies against a formidable foeMarijo Bilusic, Christopher Heery, Ravi A Madan
The Journal of Clinical Investigation|December 1, 2022
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?Nahuel Peinetti, Marijo Bilusic, Kerry L Burnstein
Oncology (Williston Park, N.Y.)|November 19, 2014
Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefieldJoseph W Kim, Marijo Bilusic, Elizabeth R Plimack
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2017
Immunotherapy of Prostate Cancer: Facts and HopesMarijo Bilusic, Ravi A Madan, James L Gulley
Clinical Genitourinary Cancer|July 8, 2014
Spontaneous tumor lysis syndrome in renal cell carcinoma: a case reportScott Michael Norberg, Michelle Oros, Mark Birkenbach, et al.
Human Vaccines & Immunotherapeutics|March 24, 2025
Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapyChinmay T Jani, Aysswarya Manoharan, Peter J DeMaria, et al.
Cancers|November 12, 2013
Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of responseJoseph W Kim, Marijo Bilusic, Christopher J Heery, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|January 12, 2021
Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?Marijo Bilusic, James L Gulley
Urologic Oncology|February 12, 2015
Targeted radionuclides for prostate cancer bone metastasesTimothy Ito, Marijo Bilusic, David Chen
BMC Nephrology|November 24, 2016
Nivolumab-associated acute glomerulonephritis: a case report and literature reviewKyungsuk Jung, Xu Zeng, Marijo Bilusic
Vaccine|July 12, 2011
Immunotherapy in prostate cancer: emerging strategies against a formidable foeMarijo Bilusic, Christopher Heery, Ravi A Madan
The Journal of Clinical Investigation|December 1, 2022
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?Nahuel Peinetti, Marijo Bilusic, Kerry L Burnstein
Oncology (Williston Park, N.Y.)|November 19, 2014
Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefieldJoseph W Kim, Marijo Bilusic, Elizabeth R Plimack
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2017
Immunotherapy of Prostate Cancer: Facts and HopesMarijo Bilusic, Ravi A Madan, James L Gulley
Clinical Genitourinary Cancer|July 8, 2014
Spontaneous tumor lysis syndrome in renal cell carcinoma: a case reportScott Michael Norberg, Michelle Oros, Mark Birkenbach, et al.
Human Vaccines & Immunotherapeutics|March 24, 2025
Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapyChinmay T Jani, Aysswarya Manoharan, Peter J DeMaria, et al.
Cancers|November 12, 2013
Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of responseJoseph W Kim, Marijo Bilusic, Christopher J Heery, et al.
Pageof 8